a February 23rd, 2012

  1. New variety of Broccoli launched

    February 23, 2012 by Neuschwanstein

    Millions of parents face a daily battle with their children to get them to ‘eat their greens’.

    Encouragement, bribery and threats turn many mealtimes into a warzone.

    However, Marks & Spencer is to offer a new variety of the vegetable super-food that could find youngsters are happy to ‘eat their whites’.

    The new broccoli is milder tasting, with hints of sweetness, and could well encourage youngsters to try a food that has not first been covered in batter and deep fried.

    The White Gold Sprouting Broccoli is a long-standing heritage variety, however it has not previously been available on the high street.

    M&S said: ‘It is sweeter and more succulent than the more common green or purple versions. The creamy white spears have a mild flavour that will even encourage children who don’t like their ‘greens’ to eat vegetables.

    ‘Despite not having such a strong colour, it is just as packed with vitamin C as its green and purple counterparts and is a good source of caretenoids, iron, folic acid, calcium, fibre and vitamin A.

    Broccoli

    Broccoli

    The chain’s produce experts, Simon Coupe, said: ‘We’re always working with our suppliers to find new fruit and vegetables and bring back forgotten old favourites.


    ‘Even kids who don’t like to ‘eat their greens’ will love it.’

    The variety is produced in Boston, Lincolnshire by specialist sprouting broccoli grower Richard Pettitt of Franklyn’s Farm, where the soil is high in nutrients. The family has been growing vegetables there for four generations.

    The word broccoli comes from the Italian word brocco meaning branch or arm.

    Sprouting broccoli is the original form of broccoli and was first cultivated by the Romans; however, it has only been widely grown in the UK for the last 30 years.

    White Gold Sprouting Broccoli is available from M&S stores nationwide from next week priced at £1.99 for 200g.


  2. New Pancreatic cancer drug on trial

    February 23, 2012 by Neuschwanstein

    Scientists say they may have found a new weapon against pancreatic cancer after promising early trial results of an experimental drug combination.

    Giving the chemotherapy agent gemcitabine with an experimental drug called MRK003 sets off a chain of events that ultimately kills cancer cells, studies in mice show.

    Patients are now testing the treatment to see if it will work for them.

    The Cancer Research UK-funded trials are being carried out in Cambridge.

    Father-of-two Richard Griffiths, 41, from Coventry, has been on the trial since being diagnosed with pancreatic cancer in May 2011.

    “After six cycles of treatment, a scan showed the tumours had reduced and so I have continued with the treatment,” he said.

    “The trial gives you hope – I really feel I can do this with the science behind me.”

    Pancreatic cancer

    Pancreatic cancer

    Cancer Research UK says it is prioritising research into pancreatic cancer because the survival rate still remains dismally low.

    About 8,000 people in the UK are diagnosed with pancreatic cancer each year, and the disease is the fifth most common cause of cancer death in the UK.


    Survival rates are very low in relation to other cancers, and the length of time between diagnosis and death is typically short, usually less than six months.

    The most recent data for England show that about 16% of patients survive the disease beyond 12 months after diagnosis – prompting the need for new treatments.

    Professor Duncan Jodrell, who is leading the trials at the University of Cambridge, said: “We’re delighted that the results of this important research are now being evaluated in a clinical trial, to test whether this might be a new treatment approach for patients with pancreatic cancer, although it will be some time before we’re able to say how successful this will be in patients.”

    In total, about 60 patients with advanced pancreatic cancer will be recruited for the first Phase I/II clinical trial.